Charles E. Mowbray

2.8k total citations · 1 hit paper
51 papers, 1.8k citations indexed

About

Charles E. Mowbray is a scholar working on Public Health, Environmental and Occupational Health, Epidemiology and Organic Chemistry. According to data from OpenAlex, Charles E. Mowbray has authored 51 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Public Health, Environmental and Occupational Health, 23 papers in Epidemiology and 19 papers in Organic Chemistry. Recurrent topics in Charles E. Mowbray's work include Research on Leishmaniasis Studies (22 papers), Trypanosoma species research and implications (19 papers) and Synthesis and Biological Evaluation (10 papers). Charles E. Mowbray is often cited by papers focused on Research on Leishmaniasis Studies (22 papers), Trypanosoma species research and implications (19 papers) and Synthesis and Biological Evaluation (10 papers). Charles E. Mowbray collaborates with scholars based in United Kingdom, Switzerland and United States. Charles E. Mowbray's co-authors include Jeremy N. Burrows, Takushi Kaneko, Rob Hooft van Huijsduijnen, Kiyoshi Kita, Peter Warner, Dennis M. Schmatz, Ken Duncan, Stéphanie Braillard, Manos Perros and Romuald Corbau and has published in prestigious journals such as Nature Communications, SHILAP Revista de lepidopterología and Nature Reviews Drug Discovery.

In The Last Decade

Charles E. Mowbray

49 papers receiving 1.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Hit and lead criteria in drug discovery for infectious diseases of the developing world

2015 431 citations Jeremy N. Burrows, Ken Duncan et al. Nature Reviews Drug Discovery profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Charles E. Mowbray United Kingdom	21	810	795	637	406	319	51	1.8k
Mariano Zalis Brazil	22	942 1.2×	253 0.3×	249 0.4×	267 0.7×	220 0.7×	75	1.7k
Lyn‐Marié Birkholtz South Africa	22	858 1.1×	310 0.4×	170 0.3×	717 1.8×	195 0.6×	92	1.6k
Francisco‐Javier Gamo Spain	23	1.3k 1.6×	403 0.5×	314 0.5×	962 2.4×	404 1.3×	70	2.4k
Livia Vivas United Kingdom	23	802 1.0×	605 0.8×	166 0.3×	392 1.0×	217 0.7×	41	1.6k
Pedro Cravo Portugal	28	1.4k 1.8×	340 0.4×	319 0.5×	484 1.2×	235 0.7×	76	2.3k
Silvia Parapini Italy	30	1.2k 1.4×	964 1.2×	187 0.3×	728 1.8×	239 0.7×	113	2.7k
Arba L. Ager United States	28	1.1k 1.4×	536 0.7×	193 0.3×	335 0.8×	329 1.0×	54	1.9k
Esperanza Herreros Spain	20	691 0.9×	304 0.4×	202 0.3×	324 0.8×	251 0.8×	39	1.4k
Radim Nencka Czechia	28	532 0.7×	305 0.4×	321 0.5×	1.1k 2.6×	936 2.9×	90	2.4k
Lucia Gerena United States	26	1.2k 1.5×	871 1.1×	164 0.3×	538 1.3×	254 0.8×	43	2.1k

Countries citing papers authored by Charles E. Mowbray

Since Specialization

Citations

This map shows the geographic impact of Charles E. Mowbray's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Charles E. Mowbray with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Charles E. Mowbray more than expected).

Fields of papers citing papers by Charles E. Mowbray

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Charles E. Mowbray. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Charles E. Mowbray. The network helps show where Charles E. Mowbray may publish in the future.

Co-authorship network of co-authors of Charles E. Mowbray

This figure shows the co-authorship network connecting the top 25 collaborators of Charles E. Mowbray. A scholar is included among the top collaborators of Charles E. Mowbray based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Charles E. Mowbray. Charles E. Mowbray is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Bocxlaer, Katrien Van, Hilde Rosing, Alwin D. R. Huitema, et al.. (2024). Development and validation of ultra-performance liquid chromatography tandem mass spectrometry methods for the quantitative analysis of the antiparasitic drug DNDI-6148 in human plasma and various mouse biomatrices. Journal of Chromatography B. 1250. 124377–124377.

Mowbray, Charles E., et al.. (2024). Immunotherapeutic Strategies as Potential Treatment Options for Cutaneous Leishmaniasis. Vaccines. 12(10). 1179–1179. 4 indexed citations

Touret, Franck, Jean‐Sélim Driouich, Maxime Cochin, et al.. (2024). Further preclinical characterization of molnupiravir against SARS-CoV-2: Antiviral activity determinants and viral genome alteration patterns. Heliyon. 10(10). e30862–e30862. 2 indexed citations

Slafer, B. W., Marco A. Dessoy, Eun Lee, et al.. (2024). Synthesis and Anti-Trypanosoma cruzi Activity of 3-Cyanopyridine Derivatives. ACS Omega. 9(20). 22360–22370. 1 indexed citations

Machingaidze, Shingai, Carmen Pérez Casas, Ruxandra Draghia‐Akli, et al.. (2024). The case for a global therapeutics development coalition: Building a therapeutics pipeline for pandemic and endemic diseases. SHILAP Revista de lepidopterología. 4(8). e0003654–e0003654. 1 indexed citations

Malavige, Gathsaurie Neelika, Peter Sjö, Kavita Singh, et al.. (2023). Facing the escalating burden of dengue: Challenges and perspectives. SHILAP Revista de lepidopterología. 3(12). e0002598–e0002598. 34 indexed citations

Júnior, Celso de Oliveira Rezende, Adriano D. Andricopulo, An Matheeussen, et al.. (2022). Hit-to-lead optimization of a 2-aminobenzimidazole series as new candidates for chagas disease. European Journal of Medicinal Chemistry. 246. 114925–114925. 5 indexed citations

Júnior, Celso de Oliveira Rezende, Leonardo L. G. Ferreira, Adriano D. Andricopulo, et al.. (2021). 2-aminobenzimidazoles for leishmaniasis: From initial hit discovery to in vivo profiling. PLoS neglected tropical diseases. 15(2). e0009196–e0009196. 11 indexed citations

Dessoy, Marco A., An Matheeussen, Louis Maes, et al.. (2020). Hit-to-lead optimization of a benzene sulfonamide series for potential antileishmanial agents. RSC Medicinal Chemistry. 11(11). 1267–1274. 5 indexed citations

10.

Bocxlaer, Katrien Van, Diana Caridha, Brian A. Vesely, et al.. (2019). Novel benzoxaborole, nitroimidazole and aminopyrazoles with activity against experimental cutaneous leishmaniasis. International Journal for Parasitology Drugs and Drug Resistance. 11. 129–138. 55 indexed citations

11.

Thompson, Andrew M., Andrew J. Marshall, Louis Maes, et al.. (2017). Assessment of a pretomanid analogue library for African trypanosomiasis: Hit-to-lead studies on 6-substituted 2-nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]thiazine 8-oxides. Bioorganic & Medicinal Chemistry Letters. 28(2). 207–213. 20 indexed citations

12.

Burrows, Jeremy N., Ken Duncan, Rob Hooft van Huijsduijnen, et al.. (2015). Hit and lead criteria in drug discovery for infectious diseases of the developing world. Nature Reviews Drug Discovery. 14(11). 751–758. 431 indexed citations breakdown →

13.

Éperon, Gilles, et al.. (2014). Treatment options for second-stage gambiense human African trypanosomiasis. Expert Review of Anti-infective Therapy. 12(11). 1407–1417. 74 indexed citations

14.

Hay, Duncan A., Charles E. Mowbray, Michael Paradowski, et al.. (2011). Synthesis of novel histamine H4 receptor antagonists. Bioorganic & Medicinal Chemistry Letters. 22(2). 1156–1159. 14 indexed citations

15.

Mowbray, Charles E., Andrew Bell, Michelle A. Collins, et al.. (2011). Challenges of drug discovery in novel target space. The discovery and evaluation of PF-3893787: A novel histamine H4 receptor antagonist. Bioorganic & Medicinal Chemistry Letters. 21(21). 6596–6602. 29 indexed citations

16.

Williams, D. H., David R. Fenwick, Juin Fok‐Seang, et al.. (2009). Discovery of a small molecule inhibitor through interference with the gp120–CD4 interaction. Bioorganic & Medicinal Chemistry Letters. 19(17). 5246–5249. 8 indexed citations

17.

Mowbray, Charles E., Catherine Burt, Romuald Corbau, et al.. (2009). Pyrazole NNRTIs 1: Design and initial optimisation of a novel template. Bioorganic & Medicinal Chemistry Letters. 19(19). 5599–5602. 30 indexed citations

18.

Mowbray, Charles E., Romuald Corbau, Michael L. Hawes, et al.. (2009). Pyrazole NNRTIs 3: Optimisation of physicochemical properties. Bioorganic & Medicinal Chemistry Letters. 19(19). 5603–5606. 24 indexed citations

19.

Blagg, Julian, Charles E. Mowbray, David C. Pryde, et al.. (2008). Small, non-peptide C5a receptor antagonists: Part 2. Bioorganic & Medicinal Chemistry Letters. 18(20). 5605–5608. 8 indexed citations

20.

Blagg, Julian, Charles E. Mowbray, David C. Pryde, et al.. (2008). Small, non-peptide C5a receptor antagonists: Part 1. Bioorganic & Medicinal Chemistry Letters. 18(20). 5601–5604. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact